Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Clinically meaningful responses to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer.

Klimant E, Markman M, Albu DM.

Case Rep Oncol. 2013 Jan;6(1):72-7. doi: 10.1159/000346836. Epub 2013 Jan 29.

4.

[Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].

Shi YX, Xu RH, Jiang WQ, Zhang L, Lin TY, Li YH, Xia ZJ, Luo HY, Han B, Wang F, He YJ, Guan ZZ.

Ai Zheng. 2007 Dec;26(12):1381-4. Chinese.

PMID:
18076807
5.

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.

Li J, Merl M, Lee MX, Kaley K, Saif MW.

Expert Opin Drug Saf. 2010 Mar;9(2):207-13. doi: 10.1517/14740330903555181.

PMID:
20095915
6.

Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.

Liu GF, Li GJ, Zhao H.

J Cell Biochem. 2018 Jan;119(1):511-523. doi: 10.1002/jcb.26210. Epub 2017 Jul 17.

PMID:
28608558
8.

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.

Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD.

Pancreas. 2017 Feb;46(2):203-208. doi: 10.1097/MPA.0000000000000742.

9.

First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study.

Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF, Mineur L, Artru P, André T, Louvet C.

Bull Cancer. 2009 May;96(5):E18-22. doi: 10.1684/bdc.2009.0871. Epub 2009 May 12.

10.

Preoperative gemcitabine and oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma.

Di Marco M, Vecchiarelli S, Macchini M, Pezzilli R, Santini D, Casadei R, Calculli L, Sina S, Panzacchi R, Ricci C, Grassi E, Minni F, Biasco G.

Case Rep Gastroenterol. 2012 May;6(2):530-7. doi: 10.1159/000341513. Epub 2012 Aug 1.

11.

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA.

Cancer. 2008 Oct 15;113(8):2046-52. doi: 10.1002/cncr.23810.

12.

Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma.

Baize N, Abu Shalaa A, Berthier F, Demarquay JF, Bernard JL, Rahili A, Piche T, Huet PM, Tran A, Caroli-Bosc FX.

Gastroenterol Clin Biol. 2005 Oct;29(10):1006-9.

PMID:
16435507
13.

Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer.

Tudini M, Palluzzi E, Cannita K, Mancini M, Santomaggio A, Bruera G, Baldi PL, Pelliccione M, Ricevuto E, Ficorella C.

Oncol Rep. 2012 Feb;27(2):423-32. doi: 10.3892/or.2011.1517. Epub 2011 Oct 21.

PMID:
22020810
15.

Current Standards of Chemotherapy for Pancreatic Cancer.

Saung MT, Zheng L.

Clin Ther. 2017 Nov;39(11):2125-2134. doi: 10.1016/j.clinthera.2017.08.015. Epub 2017 Sep 19. Review.

PMID:
28939405
16.

Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.

Abrams TA, Meyer G, Meyerhardt JA, Wolpin BM, Schrag D, Fuchs CS.

Oncologist. 2017 Aug;22(8):925-933. doi: 10.1634/theoncologist.2016-0447. Epub 2017 May 5.

PMID:
28476943
17.
18.

Chemoresistance in pancreatic cancer: Emerging concepts.

Gnanamony M, Gondi CS.

Oncol Lett. 2017 Apr;13(4):2507-2513. doi: 10.3892/ol.2017.5777. Epub 2017 Feb 24.

19.

Seventy-two Cycles of FOLFIRINOX: Long Term Treatment in a Patient with Metastatic Adenocarcinoma of the Pancreatic Tail.

Tiller M, Gundling F, Schepp W, Fuchs M.

JOP. 2015 Mar 20;16(2):205-8. doi: 10.6092/1590-8577/2962.

20.

Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.

Adamska A, Elaskalani O, Emmanouilidi A, Kim M, Abdol Razak NB, Metharom P, Falasca M.

Adv Biol Regul. 2017 Nov 22. pii: S2212-4926(17)30176-8. doi: 10.1016/j.jbior.2017.11.007. [Epub ahead of print] Review.

PMID:
29221990

Supplemental Content

Support Center